Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent

2.8 / 5 stars · 68/120 Roast Me

REPLIMUNE GROUP, INC. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent

REPLIMUNE GROUP, INC. (REPL) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent of $582.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent · last filed 2026-08-14

  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $582.00K.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$40.00K.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $482.00K, a 84.50% decline year-over-year.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $751.00K.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for fiscal 2026 was $255.00K, a 46.55% increase from fiscal 2025.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for fiscal 2025 was $174.00K.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for fiscal 2024 was -$826.00K, a 115.06% decline from fiscal 2023.
  • REPLIMUNE GROUP, INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax, portion attributable to parent for fiscal 2023 was $5.48M, a 633.02% increase from fiscal 2022.
Period endOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent 3 monthOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent 6 monthOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent 9 monthOther Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent 12 month
2026-06-30$582.00K
10-Q · filed 2026-08-14
$542.00K
derived: sum of 2 quarters · filed 2026-08-14
$1.02M
derived: sum of 3 quarters · filed 2026-08-14
$1.77M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$40.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$442.00K
derived: sum of 2 quarters · filed 2026-06-29
$1.19M
derived: sum of 3 quarters · filed 2026-06-29
$255.00K
10-K · filed 2026-06-29
2025-12-31$482.00K
10-Q · filed 2026-02-03
$1.23M
derived: sum of 2 quarters · filed 2026-02-03
$295.00K
10-Q · filed 2026-02-03
-$304.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30$751.00K
10-Q · filed 2026-02-03
-$187.00K
10-Q · filed 2025-11-06
-$786.00K
derived: sum of 3 quarters · filed 2026-08-14
$2.32M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$938.00K
10-Q · filed 2026-08-14
-$1.54M
derived: sum of 2 quarters · filed 2026-08-14
$1.57M
derived: sum of 3 quarters · filed 2026-08-14
-$332.00K
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$599.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$2.51M
derived: sum of 2 quarters · filed 2026-06-29
$606.00K
derived: sum of 3 quarters · filed 2026-06-29
$174.00K
10-K · filed 2026-06-29
2024-12-31$3.11M
10-Q · filed 2026-02-03
$1.21M
derived: sum of 2 quarters · filed 2026-02-03
$773.00K
10-Q · filed 2026-02-03
$1.23M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30-$1.91M
10-Q · filed 2026-02-03
-$2.34M
10-Q · filed 2025-11-06
-$1.88M
derived: sum of 3 quarters · filed 2026-02-03
-$3.17M
derived: sum of 4 quarters · filed 2026-02-03
2024-06-30-$432.00K
10-Q · filed 2026-02-03
$27.00K
derived: sum of 2 quarters · filed 2026-02-03
-$1.26M
derived: sum of 3 quarters · filed 2026-02-03
$47.00K
derived: sum of 4 quarters · filed 2026-02-03
2024-03-31$459.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22
-$829.00K
derived: sum of 2 quarters · filed 2025-05-22
$479.00K
derived: sum of 3 quarters · filed 2025-05-22
-$826.00K
10-K · filed 2025-05-22
2023-12-31-$1.29M
10-Q · filed 2025-02-12
$20.00K
derived: sum of 2 quarters · filed 2025-02-12
-$1.28M
10-Q · filed 2025-02-12
-$27.00K
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30$1.31M
10-Q · filed 2025-02-12
$3.00K
10-Q · filed 2024-11-12
$1.26M
derived: sum of 3 quarters · filed 2025-02-12
$1.42M
derived: sum of 4 quarters · filed 2025-02-12
2023-06-30-$1.30M
10-Q · filed 2025-02-12
-$47.00K
derived: sum of 2 quarters · filed 2025-02-12
$111.00K
derived: sum of 3 quarters · filed 2025-02-12
$2.44M
derived: sum of 4 quarters · filed 2025-02-12
2023-03-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16
$1.42M
derived: sum of 2 quarters · filed 2024-05-16
$3.75M
derived: sum of 3 quarters · filed 2024-05-16
$5.48M
10-K · filed 2024-05-16
2022-12-31$158.00K
10-Q · filed 2024-02-08
$2.49M
derived: sum of 2 quarters · filed 2024-02-08
$4.22M
10-Q · filed 2024-02-08
$4.37M
derived: sum of 4 quarters · filed 2024-02-08
2022-09-30$2.33M
10-Q · filed 2024-02-08
$4.07M
10-Q · filed 2023-11-07
$4.21M
derived: sum of 3 quarters · filed 2024-02-08
$4.37M
derived: sum of 4 quarters · filed 2024-02-08
2022-06-30$1.74M
10-Q · filed 2024-02-08
$1.88M
derived: sum of 2 quarters · filed 2024-02-08
$2.04M
derived: sum of 3 quarters · filed 2024-02-08
$2.26M
derived: sum of 4 quarters · filed 2024-02-08
2022-03-31$144.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18
$305.00K
derived: sum of 2 quarters · filed 2023-05-18
$524.00K
derived: sum of 3 quarters · filed 2023-05-18
$748.00K
10-K · filed 2023-05-18
2021-12-31$161.00K
10-Q · filed 2023-02-09
$380.00K
derived: sum of 2 quarters · filed 2023-02-09
$604.00K
10-Q · filed 2023-02-09
$308.00K
derived: sum of 4 quarters · filed 2023-02-09
2021-09-30$219.00K
10-Q · filed 2023-02-09
$443.00K
10-Q · filed 2022-11-03
$147.00K
derived: sum of 3 quarters · filed 2023-02-09
$695.00K
derived: sum of 4 quarters · filed 2023-02-09
2021-06-30$224.00K
10-Q · filed 2023-02-09
-$72.00K
derived: sum of 2 quarters · filed 2023-02-09
$476.00K
derived: sum of 3 quarters · filed 2023-02-09
$1.10M
derived: sum of 4 quarters · filed 2023-02-09
2021-03-31-$296.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19
$252.00K
derived: sum of 2 quarters · filed 2022-05-19
$878.00K
derived: sum of 3 quarters · filed 2022-05-19
$866.00K
10-K · filed 2022-05-19
2020-12-31$548.00K
10-Q · filed 2022-02-03
$1.17M
derived: sum of 2 quarters · filed 2022-02-03
$1.16M
10-Q · filed 2022-02-03
$918.00K
derived: sum of 4 quarters · filed 2022-02-03
2020-09-30$626.00K
10-Q · filed 2022-02-03
$614.00K
10-Q · filed 2021-11-04
$370.00K
derived: sum of 3 quarters · filed 2022-02-03
$778.00K
derived: sum of 4 quarters · filed 2022-02-03
2020-06-30-$12.00K
10-Q · filed 2022-02-03
-$256.00K
derived: sum of 2 quarters · filed 2022-02-03
$152.00K
derived: sum of 3 quarters · filed 2022-02-03
-$66.00K
derived: sum of 4 quarters · filed 2022-02-03
2020-03-31-$244.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20
$164.00K
derived: sum of 2 quarters · filed 2021-05-20
-$54.00K
derived: sum of 3 quarters · filed 2021-05-20
-$236.00K
10-K · filed 2021-05-20
2019-12-31$408.00K
10-Q · filed 2021-02-04
$190.00K
derived: sum of 2 quarters · filed 2021-02-04
$8.00K
10-Q · filed 2021-02-04
$199.00K
derived: sum of 4 quarters · filed 2021-02-04
2019-09-30-$218.00K
10-Q · filed 2021-02-04
-$400.00K
10-Q · filed 2020-11-05
-$209.00K
derived: sum of 3 quarters · filed 2021-02-04
-$311.00K
derived: sum of 4 quarters · filed 2021-02-04
2019-06-30-$182.00K
10-Q · filed 2021-02-04
$9.00K
derived: sum of 2 quarters · filed 2021-02-04
-$93.00K
derived: sum of 3 quarters · filed 2021-02-04
-$232.00K
derived: sum of 4 quarters · filed 2021-02-04
2019-03-31$191.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
$89.00K
derived: sum of 2 quarters · filed 2020-06-03
-$50.00K
derived: sum of 3 quarters · filed 2020-06-03
-$897.00K
10-K · filed 2020-06-03
2018-12-31-$102.00K
10-Q · filed 2020-02-13
-$241.00K
derived: sum of 2 quarters · filed 2020-02-13
-$1.09M
10-Q · filed 2020-02-13
-$400.00K
derived: sum of 4 quarters · filed 2020-06-03
2018-09-30-$139.00K
10-Q · filed 2020-02-13
-$986.00K
10-Q · filed 2019-11-12
-$298.00K
derived: sum of 3 quarters · filed 2020-06-03
-$187.00K
derived: sum of 4 quarters · filed 2020-06-03
2018-06-30-$847.00K
10-Q · filed 2020-02-13
-$159.00K
derived: sum of 2 quarters · filed 2020-06-03
-$48.00K
derived: sum of 3 quarters · filed 2020-06-03
$576.00K
derived: sum of 4 quarters · filed 2020-06-03
2018-03-31$688.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-03
$799.00K
derived: sum of 2 quarters · filed 2020-06-03
$1.42M
derived: sum of 3 quarters · filed 2020-06-03
$2.38M
10-K · filed 2020-06-03
2017-12-31$111.00K
10-Q · filed 2019-02-14
$735.00K
derived: sum of 2 quarters · filed 2019-02-14
$1.69M
10-Q · filed 2019-02-14
2017-09-30$624.00K
10-Q · filed 2018-11-14
$1.58M
10-Q · filed 2018-11-14
2017-06-30$953.00K
10-Q · filed 2018-08-30
2017-03-31-$1.44M
10-K · filed 2019-06-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B